Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Efficacy of Biosimilar Insulin MK-1293 versus Originator Glargine

Conference Lecture with Philip D. Home / ADA 76th Scientific Sessions, New Orleans, June ‘16

Conference Interview: ADA 76th Scientific Sessions, New Orleans, June ‘16 (2)

Philip D. Home, MD, PhD, Newcastle Diabetes Centre and University of Newcastle, Newcastle, UK, presented results of a trial comparing  biosimilar MK-1293 with the original insulin glargine at the 76th scientific session of the American Diabetes Association 2016 in New Orleans, US, June 10-14.  

Efficacy of MK-1293

MK-1293 biosimilar insulin designed to be similar to his originator biological insulin glargine (IGlar, Lantus®). MK-1293 was tested in a clinical study with 506 patients with type I diabetes randomized to the new MK-1293 and insulin glargine.

Endpoints were HBA1c, hypoglycemia and fasting glucose. HBA1c declines similarly with no differences between the biosimilar and the originator. The confidence interval was equivalent and non-inferior. For the other measures - fasting glucose and hypoglycemia - no difference between MK-1293 and the original IGlar was observed.


Safety of MK-1293

With regard to adverse effects MK-1293 and the originator share similar profiles. Immunological events were very few and similar between MK-1293 and IGlar. No relationship could be discerned between the antibody titres and neutralizing antibodies in the population.

The pharmacological and pharmacokinetical studies comparing MK-1293 and IGlar in patients with  type I diabetes demonstrated the same profile in terms of concentration and activity.



The therapeutic profile of MK-1293 and IGlar in patients with type I diabetes is the same. A similar result was obtained studying patients with type II diabetes.

















Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.

Search this site

Search form


Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk